FiercePharma  Jun 28  Comment 
Big Pharma hits another ad-spending high in 2015, thanks to Novo, Valeant and more bbulik Tue, 06/28/2016 - 16:49
Reuters  Jun 28  Comment 
Britain's vote to leave the European Union has made a deadline on Thursday for potential bidders to sign up for the planned sale of Portugal's Novo Banco too tight, CEO of...
Motley Fool  Jun 22  Comment 
The latest figures peg the addressable diabetes population in the hundreds of millions of patients, and it's growing fast worldwide.
FiercePharma  Jun 22  Comment 
Novo's Tresiba hits the airwaves with new TV campaign tracystaton Wed, 06/22/2016 - 09:20
FierceBiotech  Jun 22  Comment 
After ousting former CEO, Novo A/S puts Kutay in charge of $57B investment vehicle ntaylor Wed, 06/22/2016 - 03:19
Motley Fool  Jun 20  Comment 
GLP-1 drugs like Novo Nordisk's Victoza are a major advance in the treatment of diabetes, a condition suffered by hundreds of millions of people worldwide.
Benzinga  Jun 15  Comment 
Novo Nordisk A/S (ADR) (NYSE: NVO) presented data at the American Diabetes Association on Monday and trusted the doctors in attendance to not share the confidential and market-moving data they just saw. As if that would actually happen in the...
FierceBiotech  Jun 15  Comment 
Rottweiler tested, Novo and Sofinnova back $33M round for Rgenix john_carroll Wed, 06/15/2016 - 07:57
Benzinga  Jun 14  Comment 
The Dow fell 0.52 percent to 17,639.76, while the NASDAQ composite index declined 0.42 percent to 4,828.30. The broader Standard & Poor's 500 index dropped 0.47 percent to 2,069.30. The worst performing industries in the market today...
newratings.com  Jun 14  Comment 
WASHINGTON (dpa-AFX) - Novo Nordisk Canada Inc. announced that Victoza (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke...

You may also be interested in articles related to Novo nordisk a/s (nvo):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki